CN102626374A - Medical skin care agent and preparation method thereof - Google Patents
Medical skin care agent and preparation method thereof Download PDFInfo
- Publication number
- CN102626374A CN102626374A CN2012101304950A CN201210130495A CN102626374A CN 102626374 A CN102626374 A CN 102626374A CN 2012101304950 A CN2012101304950 A CN 2012101304950A CN 201210130495 A CN201210130495 A CN 201210130495A CN 102626374 A CN102626374 A CN 102626374A
- Authority
- CN
- China
- Prior art keywords
- skin
- medical skin
- chitosan
- nursing agent
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medical skin care agent and a preparation method thereof, wherein, the medical skin care agent provided in the invention mainly comprises chitosan or derivatives thereof, a gelling agent and preservative. Specifically, the gelling agent is advantaged in that: ceramide, a mixture of sphingolipids and phospholipids, ceramide analogue and the like are used to form a layered-structure gel phase structure which is similar to skin lipoid structure and capable of enhancing the lipoid structure of the skin itself, thereby realizing the function of repairing skin barrier; due to the adding of the chitosan or the derivatives thereof in the medical skin care agent, the medical skin care agent is provided with broad-spectrum anti-microbial property and can effectively repair common skin inflammation of redness, swelling, peeling, itching and the like for dry, damaged and sensitive skin, thereby realizing anti-microbial function and anti-inflammation function in medical skin care.
Description
Technical field
The present invention relates to medical skin nursing agent field, relate in particular to a kind of medical skin nursing agent and preparation method thereof with anti-inflammation, reparation skin barrier.
Background technology
In the prior art, the compositions or the reagent that much are used for skin nursing all have the function of repairing skin barrier, and the raw material of use wherein generally adopts sugar alcohol, calcium ion, Fructus Vitis viniferae resin, alkanediol, Chinese herbal medicine extract, probiotic microorganisms etc.But above-mentioned composition does not all have the function of anti-inflammation; Can only use in ordinary cosmetics; Thereby can not be directed against dermatitis symptoms such as dryness, impaired, sensitive-skinned common redness, decortication, pruritus and repair, be not suitable for the antibacterial and anti-inflammation functions of skin nursing.
The patent No.: 200580014813.5 document discloses and has used fan lupin total extract and chroman derivatives and 1-benzopyran derivatives as antiinflammatory, and can repair skin barrier and wound.But fan Seem Lablab Album abstraction process is complicated, be through ultrafiltration extraction separation repeatedly, and the enzyme hydrolysis operation, raw material obtains and is unfavorable for industrial productionization, and its expensive is not suitable for the preparation of the antibiotic barrier preparation for repairing of skin of extensive use.
Therefore, prior art awaits to improve and development.
Summary of the invention
Deficiency in view of above-mentioned prior art the object of the present invention is to provide a kind of medical skin nursing agent and preparation method thereof, is intended to solve existing medical skin nursing agent and can not repairs the high problem of skin barrier and wound or preparation cost.
Technical scheme of the present invention is following:
A kind of medical skin nursing agent wherein, by weight percentage, comprises gel 0.6 ~ 11%, antiseptic 0.03 ~ 2%, and surplus is a water;
Said gel comprises one or more the mixture in ceramide, sphingolipid and phospholipid mixture, type ceramide.
Described medical skin nursing agent, wherein, said medical skin nursing agent also comprises:
Chitosan or derivatives thereof 0.5 ~ 5%.
Described medical skin nursing agent, wherein, said medical skin nursing agent also comprises:
PH regulator agent 0.1 ~ 1%;
Acrylate cross linked copolymer 0.01 ~ 2%;
Described medical skin nursing agent, wherein, said acrylate cross linked copolymer is one or more in C10-30 alkyl acrylate interlinkage copolymer, crosslinked allyl sucrose acrylic ester or the acrylates alkyl acrylate copolymer; Said pH regulator agent is triethanolamine, diethanolamine or citric acid.
A kind of medical skin nursing agent, wherein, said medical skin nursing agent by weight percentage, comprises following component:
Ceramide 0.1 ~ 1%;
Hydrolecithin 0.5 ~ 1.5%;
Stearic acid cholesterol fat 0.1 ~ 0.5%;
Carboxymethyl chitosan 0.1 ~ 5%;
Triethanolamine 0.1 ~ 1%;
Two phenyl phenol 0.03 ~ 1%;
C10-30 alkyl acrylate interlinkage copolymer 0.01 ~ 1%;
Distilled water surplus.
A kind of medical skin nursing agent, wherein, said medical skin nursing agent by weight percentage, comprises following component:
Glucosylceramide class and glycosyl sphingolipid 0.1 ~ 1%;
Soybean lecithin 0.5 ~ 1.5%;
N-acetyl-D-amino glucose 0.1 ~ 1%;
Crosslinked allyl sucrose acrylic ester 0.01 ~ 1%;
Diethanolamine 0.1 ~ 1%;
3-iodo-2-propynyl butyl carbamate 0.01 ~ 2%;
Acrylates alkyl acrylate copolymer 0.01 ~ 1%;
MEA 0.1 ~ 1%;
Distilled water surplus.
A kind of medical skin nursing agent, wherein, said medical skin nursing agent by weight percentage, comprises following component:
Vegetative nerve amide 0.1 ~ 1%;
Maleic acid ricinolein 0.5 ~ 1.5%;
Hyaluronic acid-like chitosan 0.1 ~ 5%;
Squalane 1 ~ 3%;
Acrylic ester octyl acrylamide copolymer 0.01 ~ 1%;
Citric acid 0.01 ~ 1%;
Methylisothiazolinone and chlormethylisothiazo,ine ketone 0.03 ~ 1%;
Distilled water surplus.
A kind of medical skin nursing agent, wherein, said medical skin nursing agent by weight percentage, comprises following component:
Tristerin, behenyl alcohol, citric acid, stearic acid, myristyl alcohol, lecithin, lauryl alcohol and spermol totally 1 ~ 10%;
Glucosylceramide class and glycosyl sphingolipid 0.1 ~ 1%;
Sucrose monostearate 0.5 ~ 5%;
N-carboxybutyl chitosan 0.01 ~ 0.03;
D-glucosamine sodium sulfate salt 0.1 ~ 5%;
C10-30 alkylol acrylamide acid esters cross linked polymer 0.01 ~ 1%;
Triethanolamine 0.1 ~ 1%;
Phenoxyethanol 0.1 ~ 5%;
Distilled water surplus.
A kind of method for preparing of above-mentioned medical skin nursing agent is characterized in that, may further comprise the steps:
Step 1, acrylate cross linked copolymer is disperseed swelling in water;
Step 2, chitosan and chitosan derivatives composition is water-soluble in advance;
Step 3, get an amount of gel and mix with the good acrylate cross linked copolymer of swelling earlier, stir; Add the pH regulator agent, regulate pH value to PH6.5 ~ 7.0;
Step 4, good chitosan and the chitosan derivatives composition of adding dissolving, remaining gel stirs at a slow speed;
Step 5, adding antiseptic stir.
Beneficial effect: medical skin nursing agent of the present invention; Use ceramide, sphingolipid and phospholipids compounds to form lamellated gel phase structure; The lipoid structural similarity of this structure and skin can strengthen the lipoid structure of skin itself, thereby reaches the purpose of repairing skin barrier.In addition; Owing in the medical skin nursing agent, added the chitosan or derivatives thereof; Thereby make the medical skin nursing agent have broad spectrum antibacterial; Can effectively be directed against dryness, undermined dermatitis symptoms such as the common redness of sensitive skin, decortication, pruritus and repair, reach the antibacterial and anti-inflammation functions of medical skin nursing.
Description of drawings
Fig. 1 forms the gel phase structural representation of layer structure for medical skin nursing agent of the present invention.
The specific embodiment
The present invention provides a kind of medical skin nursing agent, and is clearer, clear and definite for making the object of the invention, technical scheme and effect, below to further explain of the present invention.Should be appreciated that specific embodiment described herein only in order to explanation the present invention, and be not used in qualification the present invention.
Easy-to-use skin-care agent provided by the present invention mainly is to be made up of chitosan or derivatives thereof, gel, antiseptic.Said gel specifically is to use materials such as ceramide, sphingolipid and phospholipid mixture, type ceramide; Can form the gel phase structure of layer structure; With similar on the skin lipoid structure, can strengthen the lipoid structure of skin itself, thereby reach the function of repairing skin barrier.
Medical skin nursing agent provided by the invention by weight percentage, comprises 0.5 ~ 5% chitosan or derivatives thereof, 0.6 ~ 11% gel, and 0.03 ~ 2% antiseptic, surplus is a water.
Skin barrier comprises the orderly lipid zone of being separated by liquid boundary, at dryness, impaired, lipoid infrastructure product that the surperficial utilization structure of sensitive skin is similar, can help the horny layer functional promotion.Contain gel in the medical skin nursing agent provided by the present invention; Gel is to use products such as ceramide, sphingolipid and phospholipid mixture, type ceramide to form; Can form the gel phase structure of layer structure, as shown in Figure 1, similar on said gel phase structure and the skin lipoid structure; Can strengthen the lipoid structure of skin itself, thereby reach the function of repairing skin barrier.
Gel described in the medical skin nursing agent of the present invention comprises one or more the mixture in ceramide, sphingolipid and phospholipid mixture, type ceramide.
Said gel can comprise one or more in ceramide, hydrolecithin, stearic acid cholesterol fat, glucosylceramide class, glycosyl sphingolipid, soybean lecithin, vegetative nerve amide, maleic acid ricinolein, squalane, tristerin, behenyl alcohol, citric acid, stearic acid, myristyl alcohol, lecithin, lauryl alcohol, spermol, glucosylceramide class or the glycosyl sphingolipid.
Ceramide is a kind of water-soluble grease metallic substance, and it is close with the structure of matter that constitutes keratodermatitis, and the water that can penetrate into very soon in skin and the horny layer combines, and forms a kind of RF, pins moisture, and it can play protection skin and moisten, moisture-keeping functions.In addition, ceramide also has the effect that prevents anaphylaxis dermatosis and inhibition melanin brown patch.Also have on the existing market ceramide as the preserve moisture product of composition of skin protection, but the kind of ceramide, content and greasyly have influence on its effect than regular meeting with other if adding proportion is improper, can let the moisture-keeping functions of original skin descend on the contrary.Through a large amount of experimentatioies, if in skin-care agent, add 0.1 ~ 1% ceramide, the skin skin protectant is had preserve moisture preferably and skin effect, the effect of vegetative nerve amide is better, and its preserving moisture and protecting skin effect is obvious.
The effective ingredient that chitosan that the present invention uses or chitosan derivatives can be used as anti-inflammation, chitosan is inhibited to the growth of various bacteria, even the Candida albicans that general antibiotic is difficult to suppress is also had inhibitory action.The broad spectrum antibacterial performance of chitosan reaches the antibacterial and anti-inflammation functions of skin nursing to dryness, impaired, redness that sensitive skin is common decortication pruritus dermatitis symptom.In addition, chitosan derivatives also has good moisture preserving water-retaining property, emollient, and is biodegradable waits good characteristic, also can repair the wetting agent and layer gel use mutually of skin barrier simultaneously.Chitosan derivatives has performances such as excellent biological compatibility, degradability, anti-inflammation and promotion wound healing, therefore in medical skin nursing agent of the present invention, can play a significant role.
Said chitosan derivatives can be N-hydroxyethyl chitosan, N-acetylated chitosan sugar, hyaluronic acid-like chitosan, carboxymethyl chitosan, N-front three chitosan hydrochloride, N-hydroxypropyl chitosan acetas, cyanoethyl (or phenylcyanide ethyl) chitosan, N-third (fourth, oneself) acylation chitosan, N-methyl (benzene) sulphonyl chitosan, N-phthalyl chitosan, the basic chitosan of N-fourth (hot, hexadecane), N-carboxybutyl chitosan, N-sulphuric acid chitosan, 6-O-hydroxyethyl chitosan, glycol-chitosan, glycerol (3-chloropropane-1; The 2-glycol) one or more in chitosan, β-D galactoside branching chitosan, 6-deoxidation chitosan, 6-O-sulfate mono (3,6-O-two sulphuric acid) chitosan, the dodecyl sodium sulfate chitosan etc.
Because chitosan and derivant thereof contain hydroxyl, amino isopolarity group, demonstrate hygroscopicity and moisture retention preferably, therefore, can be used as the modifier of skin care item.Chitosan and derivant thereof also can be used as raw material and process artificial skin, and its water absorption, breathability, histocompatibility are good.The present invention also can add acetic acid in the medical skin nursing agent, make the present invention also have analgesia, anti-infective effect.
Said antiseptic is a kind of in two phenyl phenol, phenoxyethanol, 3-iodo-2-propynyl butyl carbamate, methyl isothiazoline, the chlormethylisothiazo,ine ketone.
Also comprise pH regulator agent 0.1 ~ 1% in the said medical skin nursing agent, the pH value of medical skin nursing agent is adjusted to 6.5 ~ 7.0.Said pH regulator agent can be triethanolamine, diethanolamine or citric acid etc.
Also comprise acrylate cross linked copolymer 0.01 ~ 2% in the said medical skin nursing agent, said acrylate cross linked copolymer can be in C10-30 alkyl acrylate interlinkage copolymer, crosslinked allyl sucrose acrylic ester or the acrylates alkyl acrylate copolymer one or more.
Preferably, said medical skin nursing agent, by weight percentage, composed of the following components:
Ceramide 0.1 ~ 1%;
Hydrolecithin 0.5 ~ 1.5%;
Stearic acid cholesterol fat 0.1 ~ 0.5%;
Carboxymethyl chitosan 0.1 ~ 5%;
Triethanolamine 0.1 ~ 1%;
Two phenyl phenol (liquipar PE) 0.03 ~ 1%;
C10-30 alkyl acrylate interlinkage copolymer 0.01 ~ 1%;
Distilled water surplus.
Preferably, said medical skin nursing agent, by weight percentage, composed of the following components:
Glucosylceramide class, glycosyl sphingolipid 0.1 ~ 1%;
Soybean lecithin 0.5 ~ 1.5%;
N-acetyl-D-amino glucose 0.1 ~ 1%;
Crosslinked allyl sucrose acrylic ester 0.01 ~ 1%;
Diethanolamine 0.1 ~ 1%;
3-iodo-2-propynyl butyl carbamate 0.01 ~ 2%;
Acrylates alkyl acrylate copolymer 0.01 ~ 1%;
MEA 0.1 ~ 1%;
Distilled water surplus.
Preferably, said medical skin nursing agent, by weight percentage, composed of the following components:
Vegetative nerve amide (Vegetal ceramides BG) 0.1 ~ 1%;
Maleic acid ricinolein (CERAPHYL) 0.5 ~ 1.5%;
Hyaluronic acid-like chitosan 0.1 ~ 5%;
Squalane 1 ~ 3%;
Acrylic ester octyl acrylamide copolymer 0.01 ~ 1%;
Citric acid 0.01 ~ 1%;
Methylisothiazolinone, chlormethylisothiazo,ine ketone (Isocil SG) 0.03 ~ 1%;
Distilled water surplus.
Preferably, said medical skin nursing agent, by weight percentage, composed of the following components:
Tristerin, behenyl alcohol, citric acid, stearic acid, myristyl alcohol, lecithin, lauryl alcohol and spermol (Prolipid 141) totally 1 ~ 10%;
Glucosylceramide class, glycosyl sphingolipid (Vegetal ceramides BG) 0.1 ~ 1%;
Sucrose monostearate 0.5 ~ 5%;
N-carboxybutyl chitosan 0.01 ~ 0.03;
D-glucosamine sodium sulfate salt 0.1 ~ 5%;
C10-30 alkylol acrylamide acid esters cross linked polymer 0.01 ~ 1%;
Triethanolamine 0.1 ~ 1%;
Phenoxyethanol 0.1 ~ 5%;
Distilled water surplus.
The method for preparing of said medical skin nursing agent also is provided among the present invention, specifically may further comprise the steps:
Step 1: acrylate cross linked copolymer is disperseed swelling in water;
Step 2: chitosan and chitosan derivatives composition is water-soluble in advance;
Step 3: get an amount of gel and mix, stir with the good acrylate cross linked copolymer of first swelling; Add the PH regulator, regulate pH value to PH6.5 ~ 7.0;
Step 4: add good chitosan of dissolving and chitosan derivatives composition and add remaining gel, stir at a slow speed;
Step 5: add antiseptic, stir.
Medical skin nursing agent of the present invention, chitosan wherein and chitosan derivatives composition have broad spectrum antibacterial, can be directed against dryness, impaired, redness that sensitive skin is common decortication pruritus dermatitis symptom; Reach the antibacterial and anti-inflammation functions of medical skin nursing, multi-lamellar gel phase structure forms lipoid, can strengthen the lipoid structure of skin itself; Thereby reach the function of repairing skin barrier; And chitin among the present invention and chitin derivativ is cheap, is applicable to large-scale production medical skin nursing agent, the function that the present invention has anti-inflammation, repairs skin barrier; And cost is low, manufacturing process is simple, is fit to the industrialization volume production.
Embodiment 1
The constituent of medical skin nursing agent:
Vegetative nerve amide 0.1%, hydrolecithin 1.5%, stearic acid cholesterol fat 0.3%, carboxymethyl chitosan 0.9%, triethanolamine 0.5%, two phenyl phenol (liquipar PE) 0.06%, C10-30 alkyl acrylate interlinkage copolymer 1 %, distilled water surplus.
The preparation process:
Step 1: acrylate cross linked copolymer is disperseed swelling in water;
Step 2: chitosan and chitosan derivatives composition is water-soluble in advance;
Step 3: the gel that takes a morsel mixes with the good acrylate cross linked copolymer of swelling earlier, stirs; Add the PH regulator, regulate pH value to PH6.5 ~ 7.0;
Step 4: add dissolving good chitosan and chitosan derivatives composition and remaining gel, stir at a slow speed;
Step 5: add antiseptic, stir.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 1 skin-care agent.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 1 skin-care agent.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 1 skin-care agent is sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 1 skin-care agent is carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 2
The constituent of medical skin nursing agent:
Ceramide 1%, hydrolecithin 0.5%, stearic acid cholesterol fat 0.4%, carboxymethyl chitosan 3%, triethanolamine 1%, two phenyl phenol (liquipar PE) 0.7%, C10-30 alkyl acrylate interlinkage copolymer 0.5%, distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 2 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 2 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 2 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 2 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 3
The constituent of medical skin nursing agent:
Ceramide 1%, hydrolecithin 0.7%, stearic acid cholesterol fat 0.1%, carboxymethyl chitosan 1.5%, triethanolamine 0.1%, two phenyl phenol (liquipar PE) 1%, C10-30 alkyl acrylate interlinkage copolymer 0.01%, distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 3 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 3 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 3 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 3 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 4
The composition of medical nursing agent:
Glucosylceramide class, glycosyl sphingolipid 0.5%, soybean lecithin 0.5%, N-acetyl-D-amino glucose 0.1%; Crosslinked allyl sucrose acrylic ester 0.01%; Diethanolamine 1%, 3-iodo-2-propynyl butyl carbamate 0.01%, acrylates alkyl acrylate copolymer 1%; MEA 0.5%, distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 4 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 4 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 4 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 4 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 5
The composition of medical nursing agent:
Glucosylceramide class, glycosyl sphingolipid 0.1%, soybean lecithin 1.5%, N-acetyl-D-amino glucose 0.7%; Crosslinked allyl sucrose acrylic ester 0.5%; Diethanolamine 0.6%, 3-iodo-2-propynyl butyl carbamate 2%, acrylates alkyl acrylate copolymer 0.01%; MEA 1%, distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 5 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 5 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 5 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 5 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 6
The composition of medical nursing agent:
Glucosylceramide class, glycosyl sphingolipid 1%, soybean lecithin 1%, N-acetyl-D-amino glucose 1%; Crosslinked allyl sucrose acrylic ester 1%; Diethanolamine 0.1%, 3-iodo-2-propynyl butyl carbamate 0.5%, acrylates alkyl acrylate copolymer 0.01%; MEA 0.1%, distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 6 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 6 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 6 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 6 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 7
Tristerin, behenyl alcohol, citric acid, stearic acid, myristyl alcohol, lecithin, lauryl alcohol, spermol (Prolipid 141) 1%; Glucosylceramide class, glycosyl sphingolipid (Vegetal ceramides BG) 1%; Sucrose monostearate 0.5%; N-carboxybutyl chitosan 0.03%; D-glucosamine sodium sulfate salt 3%; C10-30 alkylol acrylamide acid esters cross linked polymer 0.5%; Triethanolamine 1%; Phenoxyethanol 2.5%; Distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 7 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 7 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 7 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 7 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 8
Tristerin, behenyl alcohol, citric acid, stearic acid, myristyl alcohol, lecithin, lauryl alcohol, spermol (Prolipid 141) 5%; Glucosylceramide class, glycosyl sphingolipid (Vegetal ceramides BG) 0.5%; Sucrose monostearate 3%; N-carboxybutyl chitosan 0.01%; D-glucosamine sodium sulfate salt 5%; C10-30 alkylol acrylamide acid esters cross linked polymer 1%; Triethanolamine 1%; Phenoxyethanol 0.1%; Distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 8 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 8 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 8 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 8 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 9
Tristerin, behenyl alcohol, citric acid, stearic acid, myristyl alcohol, lecithin, lauryl alcohol, spermol (Prolipid 141) 10%; Glucosylceramide class, glycosyl sphingolipid (Vegetal ceramides BG) 0.1%; Sucrose monostearate 5%; N-carboxybutyl chitosan 0.02%; D-glucosamine sodium sulfate salt 0.1%; C10-30 alkylol acrylamide acid esters cross linked polymer 0.01%; Triethanolamine 0.5%; Phenoxyethanol 5%; Distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 9 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 9 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 9 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 9 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 10
The medical skin nursing agent:
Vegetative nerve amide (Vegetal ceramides BG) 1%; Maleic acid ricinolein (CERAPHYL) 1%; Hyaluronic acid-like chitosan 3%; Squalane 2%; Acrylic ester octyl acrylamide copolymer 0.01%; Citric acid 0.5%; Methylisothiazolinone, chlormethylisothiazo,ine ketone (Isocil SG) 1%; Distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 10 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 10 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 10 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 10 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 11
The medical skin nursing agent:
Vegetative nerve amide (Vegetal ceramides BG) 0.5%; Maleic acid ricinolein (CERAPHYL) 1.5%; Hyaluronic acid-like chitosan 0.1%; Squalane 1%; Acrylic ester octyl acrylamide copolymer 1 %; Citric acid 0.01%; Methylisothiazolinone, chlormethylisothiazo,ine ketone (Isocil SG) 0.5%; Distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 11 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 11 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 11 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 11 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Embodiment 12
The medical skin nursing agent:
Vegetative nerve amide (Vegetal ceramides BG) 0.1%; Maleic acid ricinolein (CERAPHYL) 0.5%; Hyaluronic acid-like chitosan 5%; Squalane 3%; Acrylic ester octyl acrylamide copolymer 0.05%; Citric acid 1%; Methylisothiazolinone, chlormethylisothiazo,ine ketone (Isocil SG) 0.1%; Distilled water surplus.
Preparation process: with embodiment 1.
According to GB/T 16886.5 medical apparatus and instruments biological assessment-vitro cytotoxicity test standard, detect the cytotoxicity of present embodiment 12 skin-care agents.Detecting Cytotoxic test is agar gel diffusion test, and test result is that cell-cytotoxic reaction is not more than 1 grade (cytotoxicity is divided into 0 ~ 4 grade, and 0 grade is no cytotoxicity, and 1 grade is slight cytotoxicity, and 2 grades is the moderate cytotoxicity, and 4 grades is the moderate cytotoxicity).
According to GB/T 16886.10 medical apparatus and instruments biological assessment-stimulation and delayed hypersensitivity test, detect the skin irritation and the sensitization of present embodiment 12 skin-care agents.The irritating test of detection of skin is made up of 30 volunteers for the test of human body skin irritation, and wherein the sex proportion is no less than three minutes one.Embodiment 12 skin-care agents are sprayed at volunteer's the upper arm outside; Skin-care agent spray area diameter is 2.5cm; In the time of skin-care agent contacting skin; Begin from 15min and 30min, when 1h, 2h, 3h, 4h, 24h, 36h, 48h and 72h, all do not produce irritative response, after removing skin-care agent, all do not produce irritative response when 24h, 48h and 72h.The test of detection of skin sensitization is that the delayed hypersensitivity sealing sticks test, does experiment with albefaction Cavia porcellus healthy, that just grow up, and nursing agent should not have sensitivity response.
Embodiment 12 skin-care agents are carried out anti-microbial property test, 24h to the bacteriostasis rate of escherichia coli, staphylococcus aureus all more than 97%.
Wherein contain ceramide among embodiment 1 ~ 3 and the embodiment 10 ~ 12, moistening effect is good than embodiment 4 ~ 9.
Should be understood that application of the present invention is not limited to above-mentioned giving an example, concerning those of ordinary skills, can improve or conversion that all these improvement and conversion all should belong to the protection domain of accompanying claims of the present invention according to above-mentioned explanation.
Claims (9)
1. a medical skin nursing agent is characterized in that, by weight percentage, comprises gel 0.6 ~ 11%, antiseptic 0.03 ~ 2%, and surplus is a water;
Said gel comprises one or more the mixture in ceramide, sphingolipid and phospholipid mixture, type ceramide.
2. medical skin nursing agent according to claim 1 is characterized in that, said medical skin nursing agent also comprises:
Chitosan or derivatives thereof 0.5 ~ 5%.
3. medical skin nursing agent according to claim 2 is characterized in that, said medical skin nursing agent also comprises:
PH regulator agent 0.1 ~ 1%;
Acrylate cross linked copolymer 0.01 ~ 2%.
4. medical skin nursing agent according to claim 3; It is characterized in that said acrylate cross linked copolymer is one or more in C10-30 alkyl acrylate interlinkage copolymer, crosslinked allyl sucrose acrylic ester or the acrylates alkyl acrylate copolymer; Said pH regulator agent is triethanolamine, diethanolamine or citric acid.
5. a medical skin nursing agent is characterized in that, said medical skin nursing agent by weight percentage, comprises following component:
Ceramide 0.1 ~ 1%;
Hydrolecithin 0.5 ~ 1.5%;
Stearic acid cholesterol fat 0.1 ~ 0.5%;
Carboxymethyl chitosan 0.1 ~ 5%;
Triethanolamine 0.1 ~ 1%;
Two phenyl phenol 0.03 ~ 1%;
C10-30 alkyl acrylate interlinkage copolymer 0.01 ~ 1%;
Distilled water surplus.
6. a medical skin nursing agent is characterized in that, said medical skin nursing agent by weight percentage, comprises following component:
Glucosylceramide class and glycosyl sphingolipid 0.1 ~ 1%;
Soybean lecithin 0.5 ~ 1.5%;
N-acetyl-D-amino glucose 0.1 ~ 1%;
Crosslinked allyl sucrose acrylic ester 0.01 ~ 1%;
Diethanolamine 0.1 ~ 1%;
3-iodo-2-propynyl butyl carbamate 0.01 ~ 2%;
Acrylates alkyl acrylate copolymer 0.01 ~ 1%;
MEA 0.1 ~ 1%;
Distilled water surplus.
7. a medical skin nursing agent is characterized in that, said medical skin nursing agent by weight percentage, comprises following component:
Vegetative nerve amide 0.1 ~ 1%;
Maleic acid ricinolein 0.5 ~ 1.5%;
Hyaluronic acid-like chitosan 0.1 ~ 5%;
Squalane 1 ~ 3%;
Acrylic ester octyl acrylamide copolymer 0.01 ~ 1%;
Citric acid 0.01 ~ 1%;
Methylisothiazolinone and chlormethylisothiazo,ine ketone 0.03 ~ 1%;
Distilled water surplus.
8. a medical skin nursing agent is characterized in that, said medical skin nursing agent by weight percentage, comprises following component:
Tristerin, behenyl alcohol, citric acid, stearic acid, myristyl alcohol, lecithin, lauryl alcohol and spermol totally 1 ~ 10%;
Glucosylceramide class and glycosyl sphingolipid 0.1 ~ 1%;
Sucrose monostearate 0.5 ~ 5%;
N-carboxybutyl chitosan 0.01 ~ 0.03;
D-glucosamine sodium sulfate salt 0.1 ~ 5%;
C10-30 alkylol acrylamide acid esters cross linked polymer 0.01 ~ 1%;
Triethanolamine 0.1 ~ 1%;
Phenoxyethanol 0.1 ~ 5%;
Distilled water surplus.
9. the method for preparing of a medical skin nursing agent as claimed in claim 3 is characterized in that, may further comprise the steps:
Step 1, acrylate cross linked copolymer is disperseed swelling in water;
Step 2, chitosan and chitosan derivatives composition is water-soluble in advance;
Step 3, get an amount of gel and mix with the good acrylate cross linked copolymer of swelling earlier, stir; Add the pH regulator agent, regulate pH value to PH6.5 ~ 7.0;
Step 4, good chitosan and the chitosan derivatives composition of adding dissolving, remaining gel stirs at a slow speed;
Step 5, adding antiseptic stir.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101304950A CN102626374A (en) | 2012-04-28 | 2012-04-28 | Medical skin care agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101304950A CN102626374A (en) | 2012-04-28 | 2012-04-28 | Medical skin care agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102626374A true CN102626374A (en) | 2012-08-08 |
Family
ID=46584883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101304950A Pending CN102626374A (en) | 2012-04-28 | 2012-04-28 | Medical skin care agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102626374A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173207A (en) * | 2014-08-11 | 2014-12-03 | 上海贝泰妮生物科技有限公司 | Skin barrier repairing preparation and preparation method thereof |
| CN104814881A (en) * | 2015-05-07 | 2015-08-05 | 广州市花安堂生物科技有限公司 | Moisturizing and repairing composition and epidermis biomimetic membrane liquid crystal complex constructed therefrom |
| CN105012933A (en) * | 2015-08-18 | 2015-11-04 | 吉林大学 | Minimally invasive repair gel with rana chensinensis skin polypeptide |
| CN105796718A (en) * | 2016-04-10 | 2016-07-27 | 陕西省中医医院 | Skin care agent and preparation method thereof |
| CN106511370A (en) * | 2016-11-02 | 2017-03-22 | 上海陶盛生物技术有限公司 | Bacteriostatic liquid |
| CN106727664A (en) * | 2016-11-02 | 2017-05-31 | 上海陶盛生物技术有限公司 | Carboxymethyl chitosan prepare or screen for treat pruitus product in purposes |
| CN107334782A (en) * | 2017-07-26 | 2017-11-10 | 吉林省始祖生物波医学研究院有限公司 | A kind of inhibiting bacteria and diminishing inflammation agent and its preparation method and application |
| CN107616934A (en) * | 2017-09-16 | 2018-01-23 | 长沙仲善新能源科技有限公司 | A kind of pregnant baby nurses special product additive |
| CN108852996A (en) * | 2018-09-20 | 2018-11-23 | 北京原肽干细胞医学研究院有限公司 | A kind of skin Essence and preparation method thereof for skin repair |
| CN109010205A (en) * | 2018-08-29 | 2018-12-18 | 广州四环康源化妆品有限公司 | A kind of sensitivity flesh remediation composition and preparation method thereof |
| CN110179730A (en) * | 2019-06-19 | 2019-08-30 | 广东默默化妆品有限公司 | A kind of no line maintenance frost |
| CN113143795A (en) * | 2021-05-18 | 2021-07-23 | 华熙生物科技股份有限公司 | Composition containing gamma-aminobutyric acid and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050118131A1 (en) * | 2002-02-26 | 2005-06-02 | Jung-No Lee | Novel pseudoceramides and cosmetic compositions comprising the same |
| WO2005079743A1 (en) * | 2004-02-19 | 2005-09-01 | Symrise Gmbh & Co. Kg | Use of (2-hydroxyphenyl) alcohols, and cosmetic or therapeutic formulations containing said compounds |
| CN101835449A (en) * | 2007-08-31 | 2010-09-15 | Dsmip资产有限公司 | 4-amidino benzylamines for cosmetic and/or dermatological use |
-
2012
- 2012-04-28 CN CN2012101304950A patent/CN102626374A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050118131A1 (en) * | 2002-02-26 | 2005-06-02 | Jung-No Lee | Novel pseudoceramides and cosmetic compositions comprising the same |
| WO2005079743A1 (en) * | 2004-02-19 | 2005-09-01 | Symrise Gmbh & Co. Kg | Use of (2-hydroxyphenyl) alcohols, and cosmetic or therapeutic formulations containing said compounds |
| CN101835449A (en) * | 2007-08-31 | 2010-09-15 | Dsmip资产有限公司 | 4-amidino benzylamines for cosmetic and/or dermatological use |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173207A (en) * | 2014-08-11 | 2014-12-03 | 上海贝泰妮生物科技有限公司 | Skin barrier repairing preparation and preparation method thereof |
| CN104173207B (en) * | 2014-08-11 | 2016-08-31 | 上海贝泰妮生物科技有限公司 | A kind of skin barrier preparation for repairing and preparation method thereof |
| CN104814881A (en) * | 2015-05-07 | 2015-08-05 | 广州市花安堂生物科技有限公司 | Moisturizing and repairing composition and epidermis biomimetic membrane liquid crystal complex constructed therefrom |
| CN105012933A (en) * | 2015-08-18 | 2015-11-04 | 吉林大学 | Minimally invasive repair gel with rana chensinensis skin polypeptide |
| CN105796718A (en) * | 2016-04-10 | 2016-07-27 | 陕西省中医医院 | Skin care agent and preparation method thereof |
| CN106727664A (en) * | 2016-11-02 | 2017-05-31 | 上海陶盛生物技术有限公司 | Carboxymethyl chitosan prepare or screen for treat pruitus product in purposes |
| CN106511370A (en) * | 2016-11-02 | 2017-03-22 | 上海陶盛生物技术有限公司 | Bacteriostatic liquid |
| CN107334782A (en) * | 2017-07-26 | 2017-11-10 | 吉林省始祖生物波医学研究院有限公司 | A kind of inhibiting bacteria and diminishing inflammation agent and its preparation method and application |
| CN107616934A (en) * | 2017-09-16 | 2018-01-23 | 长沙仲善新能源科技有限公司 | A kind of pregnant baby nurses special product additive |
| CN109010205A (en) * | 2018-08-29 | 2018-12-18 | 广州四环康源化妆品有限公司 | A kind of sensitivity flesh remediation composition and preparation method thereof |
| CN108852996A (en) * | 2018-09-20 | 2018-11-23 | 北京原肽干细胞医学研究院有限公司 | A kind of skin Essence and preparation method thereof for skin repair |
| CN110179730A (en) * | 2019-06-19 | 2019-08-30 | 广东默默化妆品有限公司 | A kind of no line maintenance frost |
| CN113143795A (en) * | 2021-05-18 | 2021-07-23 | 华熙生物科技股份有限公司 | Composition containing gamma-aminobutyric acid and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102626374A (en) | Medical skin care agent and preparation method thereof | |
| Juncan et al. | Advantages of hyaluronic acid and its combination with other bioactive ingredients in cosmeceuticals | |
| CN106727164B (en) | A kind of moisture-keeping composition and its preparation method and application | |
| CN104736136B (en) | Beauty and make-up is used or medicinal moisturizing ingredient | |
| CN105997828B (en) | Smear water light Essence | |
| CN105902408B (en) | Cosmetic composition containing brown alga and red algae essence | |
| CN108143702A (en) | Efficient whitening and moisturizing mask liquid, mask and preparation method of mask liquid | |
| CN105663020A (en) | Spraying water with long-acting moisture-preserving capacity and preparation method thereof | |
| CN104027271B (en) | Emulsion and preparation method thereof | |
| CN109846757A (en) | A kind of bionical composition of sebum and the cosmetics comprising it | |
| CN109172388A (en) | Ceramide III containing liposome has anti-aging, the facial mask liquid of sebum barrier reparation and preparation method thereof | |
| CN112006954B (en) | Shampoo and preparation method thereof | |
| CN109998986A (en) | One kind two splits yeast freeze-dried powder preparation and preparation method thereof | |
| CN110433113A (en) | A kind of essence dew and preparation method containing the anti-ageing composition of moisturizing | |
| CN108113894A (en) | A kind of infant's activity milky lotion and preparation method thereof | |
| CN108836880A (en) | A kind of Baby Care cream and preparation method thereof containing nano-silver ionic | |
| CN113952258A (en) | Plant extract moisturizing essential oil special for pregnancy and preparation process thereof | |
| CN107929166A (en) | A kind of pro-skin massage oil and preparation method thereof | |
| CN114224779A (en) | Eye repair composition and application thereof | |
| CN107693419A (en) | Nourish moisturizing camellia oleifera fruit shower cream and preparation method thereof | |
| CN109875944A (en) | A kind of facial mask liquid and preparation method thereof | |
| CN103006477A (en) | Camellia oil emollient cream | |
| CN110801412B (en) | Sebum bionic composition, application thereof and cosmetics | |
| CN104224608A (en) | Anti-wrinkle and anti-aging spirulina emulsion | |
| CN111973487A (en) | Ceramide moisturizing essence and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120808 |